Third-party peptide testing means having a synthesized batch analyzed by an independent laboratory that has no commercial stake in the result, rather than relying solely on the manufacturer’s own quality control. The core analyses are HPLC, which estimates purity, and mass spectrometry, which confirms identity, and together they answer two different questions that neither can answer alone. Because peptides are produced in discrete batches whose purification varies, testing matters at the level of the individual lot, not as a single showcase report reused across a product line.

What an independent analytical laboratory does

An independent laboratory receives a sample of a specific batch, runs defined analytical methods against it, and issues a report describing the sample, the methods, the conditions, and the results. The value lies in three properties: the analyst has no interest in the outcome, the methods and instruments are documented and traceable, and the resulting report can be checked by anyone who understands the technique.

That is distinct from in-house quality control, which is not inherently unreliable but does carry an obvious conflict of interest. In practice, well-run suppliers do both: internal release testing for process control, and independent verification for confirmation. A supplier that publishes only internal summaries with no raw data and no named facility is offering the weaker of the two.

It is also worth being precise about what a lab certifies. It certifies the sample submitted to it. If the sample was hand-picked, generously purified, or drawn from a different batch than the one sold, the report is accurate and simultaneously uninformative. Chain of custody between batch and sample is therefore as important as the analysis itself.

HPLC and mass spectrometry: two different questions

These techniques are routinely mentioned in the same breath, which obscures the fact that they measure different things and that a batch can pass one while failing the other.

	HPLC	Mass spectrometry
Question answered	How much of this sample is one dominant species?	What is that species?
Principle	Separation by differential interaction with a stationary phase	Measurement of mass-to-charge ratio of ionized molecules
Typical method	Reverse-phase HPLC with UV detection near 214 to 220 nanometres	Electrospray ionization or MALDI time-of-flight
Output	Chromatogram, with purity as percentage of total integrated peak area	Spectrum, with observed molecular weight compared to theoretical
Main blind spot	Cannot confirm the main peak is the intended compound; co-eluting species can hide	Does not quantify impurities or reveal how much of the sample the identified species represents

The combination matters. A sample that is 99 percent one compound, where the compound is not the sequence ordered, is a failure that HPLC alone will not catch. A sample whose mass spectrum matches the target perfectly, but where the target is half the material present, is a failure that mass spectrometry alone will not catch. Documentation that includes only one technique leaves an open question.

Analyses that add further confidence

• Amino acid analysis. Hydrolyses the peptide and quantifies constituent amino acids, providing composition confirmation independent of the mass measurement.
• Peptide content determination. Establishes how much of the material in the container is peptide rather than water and counter-ions.
• Karl Fischer titration. Quantifies residual water in the lyophilized solid.
• Counter-ion and residual solvent testing. Quantifies acetate or trifluoroacetate and any solvent carried through from synthesis.
• Bacterial endotoxin and sterility testing. Relevant to specific research applications, notably cell culture work where endotoxin is a confounder.

Why batch-level testing is the whole point

Solid-phase peptide synthesis proceeds one residue at a time, and each coupling step is efficient but not perfect. Small failure rates accumulate across a long sequence, generating deletion sequences that differ from the target by one or more residues. Purification then removes most but not all of these, and how completely it does so varies with the run, the column condition, the operator, and the scale.

The practical consequence is that two batches of the same catalogue item, made by the same facility using the same protocol, can differ measurably in purity profile. A certificate from one of them says nothing reliable about the other. This is why the meaningful question to a supplier is not whether the product has been tested, but whether the specific lot shipped has been tested and whether that report is available.

A single undated report used across an entire catalogue is the pattern to watch for. So is a report that appears under multiple product names, and a chromatogram whose baseline noise is pixel-identical between two supposedly different lots.

How to verify a vendor’s documentation

1. Match the lot. Compare the lot or batch number printed on the physical vial label to the number on the certificate. A mismatch invalidates the document regardless of how good the numbers look.
2. Check the date. The analysis date should be consistent with the production and shipping timeline. An undated report cannot be placed in time at all.
3. Identify the laboratory. The report should name the testing facility. A named laboratory can be looked up and, if necessary, contacted.
4. Look for raw traces. A summary table is a claim. A chromatogram with labelled axes, retention times, and a visible baseline, plus a mass spectrum with observed and theoretical weights, is evidence.
5. Read the method conditions. Column, gradient, mobile phase, detection wavelength, and run time should be stated. Their absence makes the purity figure uninterpretable.
6. Check internal consistency. Sequence, molecular formula, and theoretical molecular weight should agree with each other and with the product described.
7. Compare specification against result. A proper report distinguishes the acceptance criterion from the measured value and states a pass or fail.

The mechanics of reading each of those fields, and the full list of warning signs, are set out in How to Read a Peptide Certificate of Analysis (COA).

What to ask a supplier

These questions are reasonable, answerable, and revealing. A supplier with a functioning quality system will not find them difficult.

• Can you provide the certificate of analysis for the specific lot I will receive, rather than a representative example?
• Which laboratory performed the analysis, and was it independent of the manufacturer?
• Can you supply the underlying chromatogram and mass spectrum, not only the summary page?
• What purity specification applies, and by which method was it determined?
• Is peptide content reported separately from chromatographic purity?
• Is every production lot tested, or is testing performed periodically?
• What is the retest or review interval, and how is retained sample handled?
• Is endotoxin or sterility data available where the intended research application requires it?

True Form Peptides supplies products to a 99 percent or higher HPLC purity specification, and batch certificates of analysis are published on many product pages.

The limits of any certificate

Independent testing raises confidence; it does not make a batch self-verifying. A certificate describes a sample at a moment in time under stated conditions. It cannot account for what happens afterwards: a shipment held at an uncontrolled temperature, a vial stored in a frost-free freezer that cycles through defrost, or a solution subjected to repeated freeze-thaw. Those variables sit with the receiving laboratory, and they are addressed in Lyophilized Peptides: Reconstitution, Storage and Handling in the Lab.

Documentation also cannot substitute for experimental controls. Where results for a given sequence vary across the published record, material quality is one plausible explanation among several, a point relevant to comparisons such as BPC-157 vs TB-500: What the Research Literature Actually Says. Recording the lot number with every experiment is what makes that question answerable later rather than a matter of speculation.

Research use only

All materials referenced in this article are supplied strictly for laboratory research use by qualified professionals. They are not drugs, foods, supplements, or medical devices, are not approved for human or veterinary use, and must not be administered to humans or animals. This article is informational and does not constitute medical advice.

Lyophilized peptides are research materials that have been freeze-dried into a dry solid so they remain stable during shipping and storage. In a laboratory setting they are returned to solution with a suitable diluent, commonly bacteriostatic water for multi-withdrawal containers, using aseptic technique and gentle mixing rather than shaking. Once in solution, peptide stability drops sharply, so cold storage, single-use aliquoting to avoid repeated freeze-thaw, and disciplined labelling become the controlling factors in whether the material remains fit for analytical work.

What lyophilization is and why it is used

Lyophilization, or freeze-drying, removes water from a frozen sample by sublimation under vacuum, so ice passes directly to vapour without an intervening liquid phase. The result is a porous solid, often described as a cake or a fluff, occupying roughly the volume of the original frozen solution.

Water is the main driver of peptide degradation in storage. It enables hydrolysis of the peptide backbone, supports oxidation and deamidation chemistry at susceptible residues, and permits aggregation. Removing it converts a material with a short shelf life in solution into one that is comparatively stable as a solid for extended periods at low temperature.

Two visual points are worth noting on receipt. First, the cake may be barely visible at small scale, and a vial that appears empty usually is not; the material can be a thin film on the vial wall or base. Second, a collapsed, shrunken, or discoloured cake is a deviation from the appearance normally recorded on the certificate of analysis and should be documented before proceeding.

Receiving and inspecting vials

Before anything is opened, record the lot number, the stated quantity, and the condition on arrival, and confirm that these match the accompanying documentation. How to interpret that documentation is covered in How to Read a Peptide Certificate of Analysis (COA).

Allow vials that arrived cold to equilibrate to room temperature while still sealed. Opening a cold vial in a warm room draws condensation onto a hygroscopic solid, which reintroduces exactly the water that lyophilization removed. A short equilibration period costs nothing and prevents an avoidable source of degradation.

Why bacteriostatic water is the usual diluent

Bacteriostatic water is sterile water containing a small proportion of benzyl alcohol as an antimicrobial preservative. Its role in a laboratory workflow is specific: it is intended for containers that will be entered more than once, because the preservative suppresses microbial growth introduced during repeated septum punctures.

The alternatives serve different purposes:

• Sterile water without preservative. Appropriate where a container will be used once and where the preservative would interfere with a downstream assay. It offers no protection against contamination on re-entry.
• Dilute acetic acid solution. Used for peptides that dissolve poorly at neutral pH, particularly basic sequences.
• Dilute ammonium hydroxide or mild base. Occasionally used for acidic sequences, with the caveat that alkaline conditions accelerate degradation at several residue types.
• Buffers. Selected when the assay demands defined ionic strength and pH, and chosen so the buffer itself does not interfere with detection.

Benzyl alcohol is not inert to every analytical method, and it absorbs in the ultraviolet range used for some peptide detection. Where a preserved diluent would interfere with the measurement, a preservative-free option and single-use handling is the better choice.

Aseptic technique at the bench

Solutions of peptide in water are a viable growth medium. Aseptic handling is therefore about protecting the integrity of the sample, not only the tidiness of the bench.

1. Work on a cleaned surface, ideally within a laminar flow hood or on a dedicated clean bench, and wear appropriate gloves and eye protection.
2. Remove the flip cap and swab the rubber septum of both the peptide vial and the diluent vial with isopropyl alcohol, allowing it to dry rather than wiping it off.
3. Draw the diluent with a fresh sterile needle and syringe, and use a fresh needle for each vial entry. Never re-enter a container with a used needle.
4. Vent or equalize pressure as appropriate; lyophilized vials are frequently under partial vacuum, which will pull liquid in rapidly if the transfer is not controlled.
5. Direct the stream of diluent down the inner wall of the vial rather than onto the cake. A jet fired directly at the solid promotes foaming and mechanical shear.
6. Allow the solid to wet and dissolve, then swirl or roll the vial gently. Do not shake and do not vortex aggressively; both generate foam, and the air-liquid interface promotes denaturation and aggregation.
7. Inspect against a light source. The solution should be clear and free of visible particulates or fibres. Cloudiness, gel formation, or persistent undissolved material is an observation to record, not something to force into solution with heat.

If dissolution is slow, patience and gentle agitation at room temperature are usually more effective than any intervention. Where a sequence is known to be poorly soluble, the standard approach is to test a small trial portion in the intended solvent before committing the whole vial.

Storage temperatures

State	Condition	Notes
Lyophilized solid, long term	Freezer, typically minus 20 degrees Celsius or colder	Desiccated, sealed, and protected from light
Lyophilized solid, short term	Refrigerated, typically 2 to 8 degrees Celsius	Acceptable for working stock over limited periods
In solution, short term	Refrigerated, 2 to 8 degrees Celsius	Stability is sequence dependent and markedly shorter than the solid
In solution, longer term	Aliquoted and frozen at minus 20 or minus 80 degrees Celsius	Single-use aliquots only

Two practical cautions apply to freezer choice. Frost-free domestic freezers run automatic defrost cycles that repeatedly warm their contents, which is precisely the stress aliquoting is meant to avoid; a manual-defrost or laboratory freezer is preferable. And door storage sees the largest temperature swings in any freezer, so samples belong toward the back.

Freeze-thaw and stability

Each freeze-thaw cycle concentrates solutes at the advancing ice front, shifts local pH, and creates new interfaces, all of which promote aggregation and degradation. The cumulative effect is why a solution repeatedly returned to the freezer can behave differently in an assay from one thawed for the first time, even though nothing visible has changed.

The standard mitigation is to divide a solution into single-use portions immediately after preparation, in containers sized so that a portion is consumed in one session. Label each aliquot in full rather than relying on position in a box. Thaw aliquots slowly, ideally in a refrigerator or on ice rather than in warm water, and mix by gentle inversion once thawed.

Sequence chemistry determines which degradation routes matter most. Methionine, cysteine, and tryptophan residues are susceptible to oxidation; asparagine and glutamine are prone to deamidation; cysteine-containing sequences may form unintended disulfide links. Sequences with these residues generally warrant tighter storage discipline and protection from light and air.

Labelling and record-keeping

A working container that cannot be traced back to a batch is analytically worthless, however carefully it was prepared. At minimum, each label should carry the peptide name, the lot number from the original vial, the diluent used, the concentration, the date of preparation, the storage condition, and the initials of the person who prepared it.

The notebook or inventory record should additionally capture the volume of diluent added, the calculation used to arrive at the stated concentration, the appearance of the solid before dissolution and the solution afterwards, any dissolution difficulty, and the aliquot count and locations. Cross-reference the certificate of analysis for that lot so that an anomalous result months later can be traced to a documented batch. The value of lot-level documentation is discussed in Third-Party Peptide Testing: Independent Labs and Why Batch Testing Matters, and the differences between sequences that make handling non-transferable are illustrated in BPC-157 vs TB-500: What the Research Literature Actually Says.

Finally, apply a review date rather than treating a prepared solution as indefinitely valid, and dispose of expired laboratory solutions and sharps through the institution’s established waste stream.

Research use only

This article describes laboratory handling of research materials by qualified personnel and nothing else. The peptides referred to are for in vitro research use only. They are not drugs or supplements, are not approved for human or veterinary use, and must not be administered to humans or animals. Nothing here is medical advice or an instruction for use in any living subject.

BPC-157 and TB-500 are two distinct synthetic research peptides that are frequently discussed together, but they are structurally unrelated and have been investigated along different mechanistic lines. BPC-157 is a synthetic fifteen-amino-acid sequence corresponding to a fragment of a protein identified in gastric juice, while TB-500 is a short synthetic fragment corresponding to the actin-binding region of the naturally occurring protein thymosin beta-4. Both have been examined almost exclusively in preclinical laboratory models, and neither has an established, regulator-recognized profile in humans.

Why these two peptides are compared at all

The pairing is largely a product of the literature landscape rather than a shared biochemical family. Both sequences appear in preclinical studies concerned with cellular migration, vascular processes, and tissue remodelling, so search behaviour and vendor catalogues place them side by side. That co-occurrence has created an impression of interchangeability that the underlying science does not support.

Reading them accurately requires separating three things: what each molecule is, what mechanisms have been examined in laboratory models, and what has actually been established. The third category is considerably smaller than the first two.

BPC-157: origin and structure

BPC-157 is a synthetic pentadecapeptide, meaning a chain of fifteen amino acid residues. Its sequence corresponds to a partial region of a larger protein described in the literature as body protection compound, which was characterized from gastric juice. The peptide is synthetic; it is manufactured by solid-phase peptide synthesis rather than isolated from tissue.

A practical consequence of that short length is relative robustness. The literature reports that the sequence is comparatively stable in aqueous and gastric-fluid conditions used in laboratory assays, which is one reason it has appeared in a wide range of experimental designs. Stability in a buffer, however, is a physicochemical observation and says nothing about behaviour in an organism.

Mechanisms examined in preclinical models

Preclinical studies have examined several candidate pathways, with results that are exploratory rather than settled:

• Angiogenic signalling. Investigations have looked at interactions with vascular endothelial growth factor receptor pathways and at endothelial cell behaviour in culture and in rodent models.
• Nitric oxide system interaction. A recurring theme in the published work involves nitric oxide synthase pathways, studied using pharmacological inhibitors and donors in animal models.
• Growth factor and focal adhesion pathways. Laboratory reports have examined effects on fibroblast migration and on signalling intermediates associated with cell adhesion.
• Gut and vascular models. Much of the work originates from gastrointestinal research contexts, consistent with the peptide having been described in gastric juice.

TB-500: origin and structure

TB-500 is a synthetic peptide corresponding to a short region of thymosin beta-4, a small, widely distributed intracellular protein of roughly forty-three amino acids. Thymosin beta-4 is best characterized as an actin-sequestering protein: it binds monomeric actin and participates in regulating the pool of actin available for filament assembly.

The fragment marketed for research as TB-500 corresponds to the actin-binding motif of that parent protein. This is the key structural distinction from BPC-157 and the reason the two are not substitutes for one another in an experimental design. TB-500 is a fragment of a well-described endogenous human protein; BPC-157 is a fragment sequence derived from a gastric protein and is not a fragment of thymosin beta-4 or any related family member.

Mechanisms examined in preclinical models

• Actin dynamics. The best-characterized biochemical property of the parent protein is actin monomer binding, which has been studied extensively in cell-free and cell-culture systems.
• Cell migration. Because cytoskeletal reorganization underlies motility, laboratory work has examined migration of endothelial, epithelial, and other cell types.
• Vascular and remodelling models. Thymosin beta-4 has been investigated in a range of animal models concerned with tissue remodelling and vascular processes.
• Inflammatory signalling. Some preclinical reports have examined effects on inflammatory mediators, again in model systems rather than in controlled human studies.

Side-by-side comparison

Attribute	BPC-157	TB-500
Molecular class	Synthetic pentadecapeptide	Synthetic peptide fragment
Sequence origin	Partial sequence of a protein characterized from gastric juice	Actin-binding region of thymosin beta-4
Approximate length	15 residues	Short fragment, substantially shorter than the 43-residue parent protein
Primary mechanism studied	Angiogenic and nitric oxide related signalling pathways	Actin monomer binding and cytoskeletal dynamics
Relationship to a human protein	Derived from a gastric protein sequence; not a standard signalling peptide family member	Fragment of a well-characterized endogenous protein
Typical research context	Gastrointestinal, vascular, and connective tissue models	Cytoskeletal biology, cell migration, vascular and remodelling models
Evidence base	Predominantly rodent and in vitro; concentrated among a limited number of research groups	Broad literature on the parent protein; narrower literature on the fragment itself

Why they are often studied together

Where investigators have examined the two in parallel, the rationale usually cited is mechanistic complementarity rather than similarity. One line of work concerns vascular and growth-factor signalling; the other concerns the cytoskeletal machinery that cells use to move. Designing an experiment that includes both allows a researcher to probe two different layers of the same biological process within one model system.

That is a hypothesis-generating rationale, not a demonstrated synergy. Combination work in this area remains sparse, and comparative studies using matched conditions, matched purity, and blinded assessment are notably scarce for both compounds.

What is not established

This is the section that most online comparisons omit, and it is the most important one.

• Neither compound is an approved medicine anywhere. Both are supplied as research chemicals and have not been evaluated by regulators for safety or efficacy in humans.
• The human evidence base is minimal. The overwhelming majority of published work for both sequences is in vitro or in rodent models. Extrapolation from those models to any other context is not supported.
• Mechanistic breadth is not the same as demonstrated activity. A long list of examined pathways reflects exploratory research interest, not converging confirmation.
• Methodological limitations recur. Reviewers of the BPC-157 literature have noted its concentration among a small number of groups, limited independent replication, and heterogeneous methodology. The TB-500 literature carries the separate complication that findings for the full thymosin beta-4 protein are frequently attributed to the short fragment, which is not a safe inference.
• Anti-doping status. Both BPC-157 and thymosin beta-4 related peptides appear on prohibited substance lists maintained by anti-doping authorities. Researchers working near competitive sport contexts should be aware of that classification.
• Material quality is a confounder. Where purity and identity are not documented per batch, published discrepancies can reflect the material as much as the biology.

Practical considerations for laboratory comparison work

If the two are being compared experimentally, the comparison is only as good as the characterization of the materials. Confirm the sequence and molecular weight on the certificate for each lot, and check that purity was determined under stated conditions rather than quoted as a bare number. How to do that is set out in How to Read a Peptide Certificate of Analysis (COA), and the case for lot-level rather than one-off documentation is covered in Third-Party Peptide Testing: Independent Labs and Why Batch Testing Matters.

Handling also differs enough between sequences to matter. Solubility behaviour, sensitivity to repeated freeze-thaw, and appropriate storage temperature should be established for each peptide before an experiment begins rather than assumed to be shared. Those procedures are described in Lyophilized Peptides: Reconstitution, Storage and Handling in the Lab.

The short answer

BPC-157 and TB-500 are different molecules with different origins and different mechanisms under investigation. What the literature actually supports is that each has been studied in preclinical models along the lines described above, and that neither has a body of controlled human evidence behind it. Any source presenting either as a proven intervention is going well beyond the published record.

Research use only

The peptides described in this article are supplied strictly for in vitro laboratory research and analytical applications by qualified professionals. They are not drugs, supplements, or medical devices, are not approved for human or veterinary use, and must not be administered to humans or animals. This article is informational and is not medical advice.

A peptide Certificate of Analysis (COA) is the analytical record that accompanies a specific manufactured batch of a research compound, documenting what the material was found to be and how pure it was when tested. The two results that matter most are the HPLC purity figure, which estimates how much of the sample is the target peptide versus everything else, and the mass spectrometry result, which confirms the molecular identity of that target. A COA is only meaningful when it is dated, tied to a named lot number, attributed to an identifiable testing laboratory, and matched to the batch actually shipped.

What a COA is, and what it is not

A Certificate of Analysis is a snapshot of one sample drawn from one batch at one point in time. It reports measurements, not guarantees about every vial in that batch forever: a COA certifies the tested sample, and is only as representative as the sampling and the batch control behind it.

A COA is also not a safety assessment, an approval, or an endorsement of any application. It is an analytical document produced for materials handled in a laboratory setting under research-use-only terms. Peptides sold for research are not evaluated as medicines, and nothing on a COA changes that status.

The identification block: read this first

Before looking at any chromatogram, confirm the document is about the material in front of you. A usable identification block carries the product name, the peptide sequence in single-letter or three-letter amino acid code, the molecular formula, the theoretical molecular weight, the batch or lot number, the manufacture or analysis date, and the quantity per vial.

The sequence is worth reading rather than skimming. Two compounds can share a marketing name and differ in a terminal modification, such as an amidated C-terminus, and such modifications shift the expected molecular weight. If the sequence does not match what the product page describes, resolve that discrepancy before trusting anything else on the document.

HPLC purity: what the number actually measures

High-performance liquid chromatography, normally reverse-phase HPLC for peptides, separates the components of a sample as they travel through a column. Compounds that interact more strongly with the stationary phase move more slowly, so each component leaves the column at its own retention time and registers as a peak on the detector trace.

The purity percentage on a COA is almost always an area-normalization figure: the area under the main peak divided by the total area of all integrated peaks, expressed as a percentage. A result reported as 99.2 percent means the main peak accounted for 99.2 percent of the total detected peak area under those specific conditions.

Several details on the chromatogram page tell you how much weight that number deserves:

• Detection wavelength. Peptide analysis commonly uses UV detection at roughly 214 to 220 nanometres, where the peptide bond itself absorbs. Detection at 254 nanometres will under-report peptides lacking aromatic residues.
• Gradient and run time. A gradient that is too steep or a run that ends too early can hide closely eluting impurities, including deletion sequences that differ from the target by a single residue.
• Baseline quality. A drifting or noisy baseline makes integration subjective, and integration choices move the reported percentage.
• Visible minor peaks. Small peaks are normal in synthetic peptides. Their presence is not a defect; their absence on a trace that looks unnaturally flat is more suspicious than a few honest shoulders.

The mass spectrometry trace: confirming identity

HPLC tells you how much of the sample is one dominant species. It does not tell you that the dominant species is the intended peptide. Mass spectrometry answers that question by measuring the mass-to-charge ratio of ionized molecules.

Most peptide COAs use electrospray ionization (ESI-MS) or matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF). The report should state the theoretical molecular weight calculated from the sequence and the observed molecular weight found by the instrument, and the two should agree within the resolution of the method.

Electrospray spectra often show a series of multiply charged ions rather than one clean peak, which is expected behaviour rather than evidence of contamination. What deserves attention is a systematic offset between observed and theoretical mass, since a consistent difference can indicate an unintended modification or a different compound entirely.

Supporting tests you may see

Not every COA includes these, and their absence is not automatically a problem, but their presence signals a more complete analytical package.

Test	What it reports	Why it matters
Water content (Karl Fischer)	Residual moisture in the lyophilized solid	Moisture affects mass accuracy and solid-state stability
Peptide content	Proportion of the vial mass that is peptide rather than salts and water	A 99 percent pure peptide can still be well under 99 percent of the vial weight
Counter-ion content	Acetate or trifluoroacetate associated with the peptide	Explains discrepancies between net peptide and gross weight

The distinction between purity and peptide content catches people out regularly. Purity describes the composition of the peptide fraction. Peptide content describes how much of the powder in the vial is peptide at all. Both are legitimate measurements of different things.

What an acceptable specification looks like

For research peptides, a purity specification of 98 percent or higher by HPLC is a common benchmark, and specifications of 99 percent or higher are widely used for well-characterized sequences. True Form Peptides supplies products to a 99 percent or higher HPLC purity specification, and batch COAs are published on many product pages.

A specification and a result are different entries. The specification is the acceptance criterion; the result is what the batch measured. A well-formed COA shows both, with a pass or fail determination, rather than a single unlabelled number.

Red flags

The following patterns should prompt questions before a batch is accepted into inventory:

1. No date. An undated COA cannot be tied to a production run or evaluated for age.
2. No lot or batch number. Without it, the document cannot be matched to any physical vial.
3. Lot mismatch. The lot printed on the vial label differs from the lot on the COA. This is the most common and most consequential failure.
4. No testing laboratory named. An analytical report with no identifiable analyst or facility cannot be followed up or independently confirmed.
5. Numbers without traces. A summary table quoting 99.6 percent with no chromatogram and no spectrum is an assertion, not a measurement.
6. Illegible or cropped chromatograms. Missing axes, missing retention times, or images cropped so the baseline cannot be seen prevent any independent reading.
7. Identical documents across lots. If several lots share a chromatogram with pixel-identical noise, one report is being reused.
8. Sequence or molecular weight that does not match the product. The identification block should be internally consistent.
9. Therapeutic or outcome language. An analytical document describes measurements. Claims about effects do not belong on one.

Matching the COA to the batch you received

Reading a COA well is a two-document exercise. Put the vial label next to the certificate and confirm that the product name, the lot number, and the stated quantity agree. Check that the analysis date precedes the shipping date in a way that makes sense. If a vendor publishes COAs by lot, confirm that the published document is the one for your lot rather than a generic sample.

Where a supplier cannot produce a lot-specific document, ask for the report covering the batch shipped, including the underlying chromatogram and spectrum rather than a summary page. This is discussed further in Third-Party Peptide Testing: Independent Labs and Why Batch Testing Matters.

Recording and retaining COAs

Store the certificate with the inventory record for the batch, and reference the lot number in any notebook entry involving that material. When a vial is opened for laboratory work, carry the lot number onto the working label so results remain traceable months later. Labelling practice is covered in Lyophilized Peptides: Reconstitution, Storage and Handling in the Lab.

Comparing COAs across related sequences is also informative when evaluating compounds frequently studied alongside one another, a point touched on in BPC-157 vs TB-500: What the Research Literature Actually Says.

Research use only

All materials discussed here are supplied strictly for laboratory research use by qualified professionals. They are not drugs, foods, cosmetics, or medical devices, and they are not intended for human or veterinary use, diagnostic use, or any form of administration. Nothing in this article constitutes medical advice or a recommendation for use.